With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer

Nuvation Bio peeked out from stealth mode Monday to reveal $275 million in financing and an executive team stacked with biotech veterans.

The cancer drug developer, which has offices in New York and San Francisco, is led by founder, president, and CEO David Hung, the former chief executive who steered Medivation to a $14.3 billion buyout by Pfizer (NYSE: PFE) in 2016.